Current State and Demographic Trends of Medically Underserved Populations in Rare Disease Research
Manjunatha, L.; M S, S.; Dokuru, D.; Venugopal, N.; Waldrop, J. N.; Blount, L. G.; Kartha, R. V.; Rajasimha, H. K.
Show abstract
BackgroundAddressing inequities and health disparities for medically underserved populations (MUPs) is critical, as they already face systemic bias and barriers, such as historical mistrust of healthcare systems. To achieve health equity, we need systematic approaches to measuring, quantifying, and reporting diversity, equity, inclusion, and accessibility (DEIA) metrics. MethodsThe objective of the study was to analyze literature and clinical trials to summarize the current state of demographics and socioeconomic factors (SF) reporting for MUPs in US-based RD clinical research. PubMed, Cochrane Library, and ClinicalTrials.gov were searched (1983- 2023). A universal set of 30,303 unique RD terms from the Genetic and Rare Diseases Information Center, Orphanet, Rare-X, and ClinicalTrials.gov was used to filter publications and clinical trials. Publications that reported demographics or SFs, were US-based, and involved one or more RDs were included for analysis. Clinical trials that were US-based, involved an RD, and had study results posted were also included. Age, sex or gender, race, ethnicity, and SF data were extracted and analyzed using descriptive statistics. Race and ethnicity data were compared with the US census. The representation of MUPs in RD clinical research was assessed based on the frequency of publications and clinical trials reporting 13 variables. ResultsWe reviewed 234 publications and 8475 RD clinical trials. Age was the most reported demographic variable (publications: 94%; clinical trials: 100%), followed by sex or gender (86.3%; 100%). Race (50%; 45.7%) and ethnicity (29.9%; 38.5%) were less frequently reported and often in a variable format in publications compared with the ClinicalTrials.gov database. At least one SF was reported in 15.8% of the publications and 0.2% of the trials. American Indian or Native Alaskan, Asian, Hispanic, and Latino participants were significantly underrepresented compared with the US census averages. Data were largely absent for other MUPs: lesbian, gay, bisexual, transgender, and queer or questioning individuals, rural residents, veterans, immigrants, and those affected by disability and poverty. ConclusionsSignificant gaps exist in demographics and SF reporting in RD clinical research, and several MUPs are underrepresented. Therefore, a framework to enhance DEIA in RD research is urgently needed.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Trials that turn from retrospectively registered to prospectively registered: A cohort study of ‘retroactively prospective’ clinical trial registration using history data 95%
- Number of Interventional Clinical Trials Registered per Million Population per Country Worldwide 92%
- Operational Strategies among Infectious Disease Clinical Trial Sites During Pandemics: A Scoping Review 91%
Similar papers in this journal
- Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed 96%
- Results dissemination from clinical trials conducted at German university medical centres was delayed and incomplete 95%
- Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining methodological quality 94%
Similar papers in this journal
- How Informative Were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov 94%
- Exploring scalable assessment methods for terminated trials in ClinicalTrials.gov: A cohort analysis of German and Californian trials 93%
- STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol 92%
Similar papers in this journal
- Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative 91%
- Evidence Supporting EMA Drug Approvals (2020-2023): A Cross-Sectional Study of Trial Design and Outcomes 91%
- Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: a scoping review 90%
Similar papers in this journal
- Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis 91%
- Collecting mortality data via mobile phone surveys: a non-inferiority randomized trial in Malawi 90%
- Behavior-change interventions to improve antimicrobial stewardship in human health, animal health, and livestock agriculture: A systematic review 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.